Full Press Release Details
Pharmaceuticals to Present at Rodman & Renshaw 11th
Healthcare Conference
Israel - September 3, 2009 - Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB)
(http://www.oramed.com), a developer of alternative drug delivery systems,
announced today that Nadav Kidron, its Chief Executive Officer, is scheduled to
present at the Rodman & Renshaw's 11th Annual
Healthcare Conference on Friday September 11, 2009 at 10:00 a.m.
EDT. The conference will be held at the New York Palace Hotel in New
Kidron is scheduled to speak in the Fahnestock Salon on the fifth floor of the
hotel. He will discuss Oramed's strategic initiatives, updates and product
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented flagship product,
an orally ingestible insulin capsule currently in phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. The Company's
corporate and R&D headquarters are based in Jerusalem.
information, please visit http://www.oramed.com.
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relations Contacts:
USA: +1-646-240-4193
Oramed Pharmaceuticals,
Inc. | Kefar Hi-Tech 2/5 Po Box
39098, Jerusalem, Israel 91390. | www.oramed.com
011-972-2-566-0001 | Fax: 011
972-2-566-0004 | Email: